Peritoneal Carcinomatosis Clinical Trial
— Nab-PIPACOfficial title:
Combined Nabpaclitaxel Pressurized IntraPeritoneal Aerosol Chemotherapy With Systemic Nabpaclitaxel-Gemcitabine Chemotherapy for Pancreatic Cancer Peritoneal Metastases - A Single-arm, Open-label, Phase II Trial: Nab-PIPAC Trial
NCT number | NCT05371223 |
Other study ID # | 4368 |
Secondary ID | |
Status | Recruiting |
Phase | Phase 2 |
First received | |
Last updated | |
Start date | March 1, 2022 |
Est. completion date | July 30, 2025 |
Combined chemotherapy consisting of endovenous Nabpaclitaxel-Gemcitabine and Nabpaclitaxel-PIPAC may be a promising treatment for patients affected by pancreatic cancer PM who are in need of curative options. The purpose of this study is to evaluate the antitumoral activity of combined Nabpaclitaxel-PIPAC and systemic Nabpaclitaxel-Gemcitabine chemotherapy for pancreatic cancer peritoneal metastases. Secondary objectives include the evaluation of the feasibility, the safety, further assessment of the antitumoral activity, the overall and progression free survival, the QoL, the pharmacokinetics of Nabpaclitaxel PIPAC. Furthermore, the study aims to evaluate the patients' nutritional status and the molecular evolution of PM along treatment with a time-course translational research.
Status | Recruiting |
Enrollment | 38 |
Est. completion date | July 30, 2025 |
Est. primary completion date | May 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Age = 18 years; - Willing and able to provide written and informed consent; - Histological or cytological proof of pancreatic cancer; - Metastatic disease with peritoneal carcinomatosis determined by the treating physician, based on abdominal CT or MR and/or diagnostic laparotomy or laparoscopy; - Evaluable disease defined by RECIST 1.1 criteria - Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1; - Life expectancy of at least 3 months; - No contraindication for laparoscopy; - No contraindication for drugs used in the study; - Adequate bone marrow function: Absolute neutrophil count = 1500 cell./mm3; Platelets = 100000 cell./mm3; - Hemoglobin = 9 g/dl - Adequate renal function (serum creatinine up to 1.5 times the maximal limit of the local laboratory) or else based upon clinical evaluation; Exclusion Criteria: - Advanced metastatic systemic disease with clinical deterioration; - Patients with extraabdominal tumor spread; - Patients with a germline or somatic pathogenic variant involving an (Homologous Recombination Repair) HRR-related gene; - Symptoms of gastrointestinal occlusion and total parenteral nutritional support; - Patients defined as "refractory" to previous systemic treatment with Nab-paclitaxel and Gemcitabine administered for locally advanced pancreatic cancer (patients treated with Nabpaclitaxel-Gemcitabine for a locally advanced disease may be included if PM developed after at least 6 months from the end of previous chemotherapy); - History of severe and unexpected reactions to Nabpaclitaxel or Gemcitabine derivates - Known hypersensitivity reaction to drugs chemically related to Nabpaclitaxel, Gemcitabine and their excipients; - Severe cardiac disease (recent myocardial ischemia, severe cardiac arrhythmias, severe cardiac failure); - Clinical disease progression after first 2 months of systemic Nabpaclitaxel Gemcitabine chemotherapy; - Any concurrent severe, acute, or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk of associated with study participation or investigational product administration or may interfere with compliance with study procedures or the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into the study; |
Country | Name | City | State |
---|---|---|---|
Italy | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Rome |
Lead Sponsor | Collaborator |
---|---|
Fondazione Policlinico Universitario Agostino Gemelli IRCCS |
Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | The intravenous area under the curve (AUC) of paclitaxel | The concentration of paclitaxel in peritoneal samples. The penetration of paclitaxel in peritoneal tissues. | Three and a half years | |
Other | Intra-patient e intra-tumoral heterogeneity | - The germline mutational profile from blood samples | Three and a half years | |
Other | Identification of pancreatic cancer disease evolution trough pathway analysis a in primary tumor and peritoneal sites during treatments | - The genomic mutational profile of PM biopsies taken during PIPAC; | Three and a half years | |
Primary | Disease Control Rate (DCR) | The Disease Control Rate (DCR) defined as the combined incidence of complete response (CR), partial response (PR) and stable disease (SD) according to the RECIST v. 1.1 criteria during study treatments and the EOT visit. | Three and a half years | |
Secondary | The compliance to treatment | - The number of patients unable to undergo six cycles of systemic chemotherapy combined with three PIPAC cycles and reasons for discontinuation. | Three and a half years | |
Secondary | Toxicity assessed by CTCAE | The number of patients with major toxicity, defined as grade =3 according to Common Terminology Criteria for Adverse Events (CTCAE) V5.0 during the on-study evaluation phase and up to 4 weeks after the last chemotherapy administration.
The number of patients with minor toxicity, defined as grade =2 according to CTCAE v5.0 during the treatment period and up to 4 weeks after the last chemotherapy administration. |
Three and a half years | |
Secondary | Postoperative complication assessed by Clavien-Dindo | -The number of patients with major and minor postoperative complications, defined as grade =3 and grade =2 according to Clavien-Dindo, respectively, during the treatment period and up to 4 weeks after the last PIPAC procedure. | Three and a half years | |
Secondary | Antitumoral activity assessed by PRGS | -The pathological tumor response, based on the review of peritoneal biopsies collected during each PIPAC, performed by a pathologist blinded to clinical outcomes using the Peritoneal Regression Grading Score (PRGS). A patient will be considered a responder if any reduction in the PRGS during subsequent biopsies will be recorded;
(PRGS 1: Complete regression without cancer cells - PRGS 2: higher response with prevalence of regressive phenomena and only a few residual cancer cells - PRGS 3: minor response with prevalence of residual cancer cells and poor regressive phenomena - PRGS 4: no response to therapy without regressive phenomena A reduction in the PRGS during subsequent biopsies will be considered as a positive response.) |
Three and a half years | |
Secondary | Antitumoral activity assessed by PCI | -The macroscopic tumor response, based on Peritoneal Cancer Index (PCI) recorded during each PIPAC;
The PCI index will be calculated according to the Sugarbaker method, which provides the assignment of a score between 0 and 3 based on the size of peritoneal metastases (0 without lesions; 1 if diam. 0.5 cm; 2 if diam. between 0.5 and 5 cm; 3 if diam > 5 cm or coalescent lesions) observed in 12 regions of the peritoneal cavity. The maximum score is 39. |
Three and a half years | |
Secondary | Antitumoral activity assessed by ascites volume | - The macroscopic tumor response, based on ascites volume recorded during each PIPAC | Three and a half years | |
Secondary | Antitumoral activity assessed by tumor markers | - The biochemical tumor response, based on tumor markers (CEA, Ca 19.9, Ca 125) measured at different time points. | Three and a half years | |
Secondary | The Progression Free Survival (PFS) | the time between treatment start and one of the following events, whichever comes first:
radiologic progression based on RECIST criteria v. 1.1, clinical progression (eg, bowel occlusion, inability to oral feeding, refractory ascites), death; |
From treatment start until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months | |
Secondary | The Overall Survival (OS) | The Overall Survival (OS) is defined as the time between treatment start and death. | From treatment start to death, assessed up to 12 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04826432 -
Pasireotide to Reduce Clinically Relevant Digestive Leakage After Complete Cytoreductive Surgery (CRS) Plus Hyperthermic Intra-Peritoneal Chemotherapy (HIPEC) for Peritoneal Carcinomatosis
|
Phase 2 | |
Recruiting |
NCT03127774 -
Surgery and Heated Intraperitoneal Chemotherapy for Adrenocortical Carcinoma
|
Phase 2 | |
Recruiting |
NCT04024917 -
Impact of Cardiac Coherence on Anxiety in Patients Operated on for a Peritoneal Carcinosis
|
N/A | |
Active, not recruiting |
NCT03508570 -
Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis
|
Phase 1 | |
Not yet recruiting |
NCT04352894 -
Intraoperative ICG Fluorescence Imaging for Peritoneal Carcinomatosis Detection
|
N/A | |
Completed |
NCT05547568 -
A Nomogram to Predict Major Postoperative Complications After Cytoreductive Surgery and HIPEC Based on Pre and Peroperative Criteria: Which Patient Require Intensive Monitoring?
|
||
Terminated |
NCT01683864 -
Randomized Controlled Trial to Prevent Peritoneal Seeding in Gastric Cancer
|
Phase 2/Phase 3 | |
Completed |
NCT06318793 -
Preoperative Inflammatory Markers Predict Postoperative Complications After Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Colorectal Carcinomatosis
|
||
Recruiting |
NCT04547725 -
Complete Cytoreduction Followed by IP and Systemic Chemotherapies for Gastric Cancer With Peritoneal Carcinomatosis
|
N/A | |
Completed |
NCT03304210 -
PIPAC Nab-pac for Stomach, Pancreas, Breast and Ovarian Cancer
|
Phase 1 | |
Withdrawn |
NCT03682744 -
CAR-T Intraperitoneal Infusions for CEA-Expressing Adenocarcinoma Peritoneal Metastases or Malignant Ascites (IPC)
|
Phase 1 | |
Terminated |
NCT04047771 -
A Phase I Study Evaluating SCB-313 for the Treatment of Subjects With Peritoneal Carcinomatosis
|
Phase 1 | |
Recruiting |
NCT05623787 -
Diagnostic Value of Diffusion-weighted Magnetic Resonance in High-risk Colorectal and Appendiceal Neoplasms
|
N/A | |
Recruiting |
NCT05063019 -
Role of Magnetic Resonance Enterography for Predicting Peritoneal Cancer Index
|
N/A | |
Completed |
NCT02891447 -
Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer
|
Phase 2 | |
Recruiting |
NCT04231175 -
Dedicated MR Imaging vs Surgical Staging of Peritoneal Carcinomatosis in Colorectal Cancer
|
N/A | |
Not yet recruiting |
NCT04734691 -
Second Line Oxaliplatin Based Chemotherapy Alone Versus Oxaliplatin Based PIPAC and Chemotherapy in Colorectal Peritoneal Carcinomatosis : A Phase II Randomize Mutli-centric Study
|
Phase 2 | |
Recruiting |
NCT04108936 -
Longitudinal Study of CRS/HIPEC for Peritoneal Carcinomatoses
|
||
Completed |
NCT02604784 -
Study of Efficacy and Safety of Laparoscopic Intra-abdominal Chemotherapy (PIPAC) Performed in Patients With Peritoneal Carcinomatosis From Colorectal, Ovarian, Gastric Cancer and Primary Peritoneal Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT01764789 -
Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer
|
N/A |